pteridines has been researched along with Multiple Myeloma in 7 studies
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We have investigated whether this kinase plays a role in multiple myeloma (MM) using the Plk1 inhibitor BI 2536." | 7.77 | The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. ( Chevassut, TJ; Kishikova, L; Powell, FL; Stewart, HJ; Wheatley, SP, 2011) |
| " We have investigated whether this kinase plays a role in multiple myeloma (MM) using the Plk1 inhibitor BI 2536." | 3.77 | The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma. ( Chevassut, TJ; Kishikova, L; Powell, FL; Stewart, HJ; Wheatley, SP, 2011) |
| "We studied urinary excretion levels of neopterin in 30 cancer patients affected by non-Hodgkin's lymphomas, Hodgkin's disease and multiple myeloma compared to 30 healthy subjects." | 3.67 | Urinary neopterin levels in hematologic malignancies. ( Abate, G; Comella, P; Marfella, A; Nitsch, F; Perna, M; Santelli, G, 1986) |
| "Multiple myeloma is a plasma cell malignancy that causes debilitating bone disease and fractures, in which TGFβ plays a central role." | 1.51 | TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model. ( Chantry, AD; Down, JM; Evans, HR; Green, AC; Hudson, K; Lath, D; Lawson, MA; Owen, R; Paton-Hough, J; Reilly, GC; Walkley, B, 2019) |
| "Multiple myeloma is an entity of cytogenetically and genetically heterogenous plasma cell neoplasms." | 1.38 | RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma. ( Chinen, Y; Horiike, S; Iida, S; Kiyota, M; Kobayashi, T; Kuroda, J; Matsumoto, Y; Mizutani, S; Nagoshi, H; Nakayama, R; Ri, M; Sakamoto, N; Shimura, Y; Shiotsu, Y; Taniwaki, M; Yamamoto-Sugitani, M, 2012) |
| "Those of patients with multiple myeloma stage I were only raised to near the upper limit of healthy subjects." | 1.26 | Urinary neopterine in the assessment of lymphoid and myeloid neoplasia, and neopterine levels in haemolytic anaemia and benign monoclonal gammopathy. ( Fuchs, D; Grünewald, K; Hausen, A; Huber, H; König, K; Wachter, H, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (42.86) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Green, AC | 1 |
| Lath, D | 1 |
| Hudson, K | 1 |
| Walkley, B | 1 |
| Down, JM | 1 |
| Owen, R | 1 |
| Evans, HR | 1 |
| Paton-Hough, J | 1 |
| Reilly, GC | 1 |
| Lawson, MA | 1 |
| Chantry, AD | 1 |
| Stewart, HJ | 1 |
| Kishikova, L | 1 |
| Powell, FL | 1 |
| Wheatley, SP | 1 |
| Chevassut, TJ | 1 |
| McMillin, DW | 1 |
| Delmore, J | 1 |
| Negri, J | 1 |
| Ooi, M | 1 |
| Klippel, S | 1 |
| Miduturu, CV | 1 |
| Gray, NS | 1 |
| Richardson, PG | 1 |
| Anderson, KC | 1 |
| Kung, AL | 1 |
| Mitsiades, CS | 1 |
| Shimura, Y | 1 |
| Kuroda, J | 1 |
| Ri, M | 1 |
| Nagoshi, H | 1 |
| Yamamoto-Sugitani, M | 1 |
| Kobayashi, T | 1 |
| Kiyota, M | 1 |
| Nakayama, R | 1 |
| Mizutani, S | 1 |
| Chinen, Y | 1 |
| Sakamoto, N | 1 |
| Matsumoto, Y | 1 |
| Horiike, S | 1 |
| Shiotsu, Y | 1 |
| Iida, S | 1 |
| Taniwaki, M | 1 |
| Hausen, A | 1 |
| Fuchs, D | 1 |
| Grünewald, K | 1 |
| Huber, H | 1 |
| König, K | 1 |
| Wachter, H | 1 |
| Santelli, G | 1 |
| Marfella, A | 1 |
| Abate, G | 1 |
| Comella, P | 1 |
| Nitsch, F | 1 |
| Perna, M | 1 |
| Thomas, P | 1 |
| Mura, P | 1 |
| Tallineau, C | 1 |
| Bounaud, MP | 1 |
| Reiss, D | 1 |
| Bontoux, D | 1 |
7 other studies available for pteridines and Multiple Myeloma
| Article | Year |
|---|---|
TGFβ Inhibition Stimulates Collagen Maturation to Enhance Bone Repair and Fracture Resistance in a Murine Myeloma Model.
Topics: Alkaline Phosphatase; Animals; Bone Remodeling; Bortezomib; Cancellous Bone; Collagen; Disease Model | 2019 |
The polo-like kinase inhibitor BI 2536 exhibits potent activity against malignant plasma cells and represents a novel therapy in multiple myeloma.
Topics: Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; H | 2011 |
Microenvironmental influence on pre-clinical activity of polo-like kinase inhibition in multiple myeloma: implications for clinical translation.
Topics: Blotting, Western; Bone and Bones; Caspase 3; Cell Cycle; Cell Cycle Proteins; Cell Line; Cell Line, | 2011 |
RSK2(Ser227) at N-terminal kinase domain is a potential therapeutic target for multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; | 2012 |
Urinary neopterine in the assessment of lymphoid and myeloid neoplasia, and neopterine levels in haemolytic anaemia and benign monoclonal gammopathy.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic; Biopterins; Female; Humans; Hypergammaglobulinemia; Leuk | 1982 |
Urinary neopterin levels in hematologic malignancies.
Topics: Adolescent; Adult; Aged; Biopterins; Child; Female; Hodgkin Disease; Humans; Lymphoma; Male; Middle | 1986 |
[Value of the assay of urinary neopterin in multiple myeloma. Preliminary study].
Topics: Aged; beta 2-Microglobulin; Biopterins; Chromatography, High Pressure Liquid; Female; Humans; Immuno | 1985 |